Actinium Pharmaceuticals appoints Robert Daly VP, head of clinical operations.

Actinium Pharmaceuticals (ATNM) announced the appointment of Robert Daly, M.S., Ph.D., to the position of Vice President, Head of Clinical Operations, effective immediately. In this role, Dr. Daly will oversee all clinical operations, with a focus on executing Actinium's progressing pivotal Phase 3 trial for Iomab-B as a targeted conditioning agent, driving forward the Company's growing CD33 program including its advancement in targeted conditioning, as well as future clinical trial expansion for the entire pipeline. He will be supervised by Dr. Mark Berger, Actinium's CMO and will report to Actinium's Chairman and CEO, Sandesh Seth, for strategic and organizational related matters. Prior to joining Actinium, Dr. Daly served as Vice President, Clinical, at CTI BioPharma (CTIC).